Sarcoma UK Annual Report & Accounts 2016/17 by Sarcoma UK

Sarcoma UK Annual Report & Accounts for the year ended 31 March 2017

The bone & soft tissue cancer charity Registered as a charity in England and Wales (1139869) and in Scotland (SC044260) â&#x20AC;˘ A company limited by guarantee in England and Wales (7487432)

Contents

Chair of Trustees’ Statement Report of the Trustees:

Chair of Trustees’ Statement

Page 3 4 – 30

Objectives and activities Achievements and performance Governance, structure and management Financial review Statement of responsibilities of the trustees

Reference and Administrative Details

20 – 22 23

Independent Auditor’s Report to the Members of Sarcoma UK

31 – 33

Financial Statements:

34 – 47

Statement of financial activities Balance sheet Statement of cash flows Notes to the financial statements

I am very pleased to report that the charity’s income continues to grow steadily, despite a very challenging fundraising environment. Our income increased by 14% to £1,369,014, and exceeded our forecast budget. I am hugely grateful to all our supporters who, through their amazing efforts, have put Sarcoma UK into the JustGiving Top 100 charities. We raise more money per JustGiving page than most other charities and this is down to the commitment and enthusiasm of our dedicated supporters. Thank you to everyone who has raised funds for Sarcoma UK this year. Our strategy is to achieve sustainable income growth that is matched by an increased investment into our charitable objectives. I am delighted to report that we invested our largest single amount into sarcoma research this year - £491,582 – a significant increase from 2015/16 (£335,493).

Future plans

Acknowledgements

In my final year as Chair of Trustees, I am delighted to report on another year of significant development for Sarcoma UK. 2016/17 has been a pivotal year for us. As the charity partner of 10 Downing Street, we had a unique opportunity to increase awareness and build our profile for the future. A highlight of this year was our reception at 10 Downing Street, hosted by the Prime Minister Theresa May.

It has been a privilege to have served the sarcoma community for the past nine years as a member of the Board of Trustees and to have overseen the growth of Sarcoma UK from a small volunteerrun charity to a national voice for everyone affected by sarcoma – patients, family members, friends, health professionals, and researchers. During this time, I have seen a real change and increase in awareness and understanding of sarcoma. Support and information for people diagnosed with sarcoma and their families is now in place through Sarcoma UK’s team of sarcoma specialist nurses, our Support Line services and the charity’s high quality information which is available in multiple formats. I have no doubt that the continued investment that Sarcoma UK is making into ground breaking medical research will pay dividends in the coming years. However, there is still much to do. 3,800 people are diagnosed with sarcoma each year, yet many are still unaware of the personal and expert support available to them from Sarcoma UK. I would like to know that every person diagnosed with sarcoma is seen by a sarcoma specialist team and made aware of the services Sarcoma UK can provide. When I heard my sarcoma diagnosis for the first time eleven years ago, I will always remember the fear of not being able to find safe, reliable and supportive information on the internet. I am so proud of the work Sarcoma UK has accomplished in bringing this much needed support and information to people affected by sarcoma. As my term of office ends, I look back and see the incredible developments brought to life through the hard work and keen focus of both fellow trustees and staff. I look forward to seeing what Sarcoma UK does next, with great confidence that the charity will continue to maximise its impact and truly change the landscape for sarcoma. Karen Delin Chair of Trustees

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Objectives and Activities

The sarcoma landscape 1. Sarcoma is cancer. It can develop anywhere in the body. 10 people are diagnosed with sarcoma every day in the UK. 2. Sarcoma is cancer of the bone or soft tissue. 3. A key symptom of sarcoma is a lump that is increasing in size, often quickly.

The bone & soft tissue cancer charity

Sarcoma UK is the only cancer charity in the UK focusing on all types of sarcoma. Our Mission

4. Sarcoma is one of the hardest cancers to diagnose. People visit their GP more times than those with any other form of cancer before being diagnosed with sarcoma. 5. Sarcoma is usually the size of a baked bean tin when diagnosed. If sarcoma is diagnosed when it is smaller than a golf ball, it would increase the chance of survival by at least 20%. 6. People with sarcoma tend to be younger than most people with cancer. 16% of sarcomas are diagnosed in people under 30, compared to only 2% of all other cancers.

Our mission is to amplify sarcoma awareness, inspire involvement, and fund ground-breaking research to transform the lives of everyone affected by sarcoma.

Our Goals 1. More people will survive sarcoma 2. More will be known about the causes of sarcoma 3. Everyone affected by sarcoma will have access to the best treatment and care

What we do

•

Sarcoma UK works with patients, carers, supporters, health professionals

•

and researchers to drive awareness of sarcoma, promote early diagnosis and improve patient experience.

Sarcoma UK has pledged to invest over £3 million into sarcoma research by

• • •

2020 with the aim of finding effective treatment for the disease within the next 10 years.

Sarcoma UK is the only UK charity providing personal support and expert

information on sarcoma.

Sarcoma UK aims to increase survival rates by at least 10% by 2020. Early

diagnosis saves lives.

Sarcoma UK provides education and training for GPs to

help them recognise the symptoms of sarcoma.

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Sarcoma UK’s research symposium attracted 71 scientific minds from all over the world

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Achievements and Performance – Priority 1:

Initiate change to raise awareness and improve standards of treatment and care What we said we would do: 1. Increase public awareness of sarcoma so that more people know that sarcoma is cancer, through our partnership with 10 Downing Street, Sarcoma Awareness Week, and targeted engagement with the media. 2. Draw on data from the National Sarcoma Survey to work with sarcoma specialist centres, multi-disciplinary teams, and clinical nurse specialists to improve the sarcoma patient experience.

In November, Prime Minister Theresa May hosted a special reception Transforming the Landscape for Sarcoma at 10 Downing Street. people attended, including patients • 137 and their families, health professionals,

researchers, current and potential supporters, politicians and people of influence in the health sector including the Secretary of State for Health, Jeremy Hunt MP, and the National Cancer Director, Cally Palmer.

Prime Minister met privately • The with Sarcoma UK representatives, our

Patron Richard Whitehead, supporters Pippa Hatch and Andrea Siodmok, and members of Chris Martin’s family. Lindsey Bennister and Theresa May

1. Increase awareness - what we did:

Sarcoma Awareness Week 2016

The staff at the Prime Minister’s Office, 10 Downing Street, chose Sarcoma UK as their Charity of the Year 2016, in memory of Chris Martin, Principal Private Secretary to the Prime Minister who passed away of sarcoma in November 2015. During the partnership, Team 10:

a Great British Bake-Off with guests Paul Hollywood and Nadia Hussain, attended • Held by the Prime Minister David Cameron and Chancellor George Osbourne. • Completed a 12-mile assault course, Tough Mudder London West. • Held a staff summer party in aid of Sarcoma UK. volunteers from the Cabinet Office to facilitate a session at our Sarcoma • Provided Research Symposium. Sarcoma • Invited UK’s Chief Executive to present to 10 Downing Street staff.

10km dressed • Ran as Santa Claus. Sarcoma • Upskilled UK staff. £25,000 for • Raised Sarcoma UK.

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Paul Hollywood and Nadia Hussain

new infographic film about sarcoma signs and symptoms was launched for • Our Sarcoma Awareness Week and was viewed over 10,000 times (July 16 – March 17) on YouTube.

and You was a unique online photographic exhibition that captured the • Sarcoma effects of sarcoma on body image. Photographer and sarcoma patient Alison Romanzcuk shot 12 inspiring and striking portraits of people who had a personal story of sarcoma to tell. The infographic and Sarcoma and You exhibition attracted media coverage in the Daily Mirror, Yours, Mail Online, Huffington Post, London Live, and Good Morning Britain. “Can I just thank you from the heart for the stories and photos this week, they are truly inspirational. I was diagnosed with a sarcoma in my abdominal wall last October and had a large piece of wall removed and part of my left hip. I’ve had breast cancer before but sarcoma has been the bad boy. So thank you once again because of these stories I can do up my truss and hold my head up high.” H

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Achievements and Performance – Priority 1:

Initiate change to raise awareness and improve standards of treatment and care

2. Improve sarcoma patient experience - what we did: National Sarcoma Survey (2015) data and findings were widely used in • The 2016/17. This unique and extensive dataset of the experiences of 650 sarcoma patients in England and Wales has been a key tool in helping clinicians and policy makers to understand the needs and experiences of sarcoma patients to drive improvements in care.

complete dataset was made available free of charge to seven national clinical • The and research groups under a Data Transfer Agreement. from the Survey were presented verbally to the Scottish Sarcoma • Findings Network; Cancer 52; and National Cancer Research Institute sarcoma clinical

•

studies group (bone sarcoma sub-group). Academic posters were displayed at the European Society of Medical Oncology (ESMO) annual conference; the Connective Tissue Oncology Society (CTOS) annual conference; and the British Sarcoma Group annual conference.

The National Sarcoma Forum (of sarcoma specialist nurses and allied health professionals) East region analysed the data on rehabilitation and designed a questionnaire to be used by clinical nurse specialists in sarcoma clinics. The data will inform improvements in access to, and timing of, rehabilitation for sarcoma patients.

3. Other – what we did:

• We supported 11 National Sarcoma Forum regional meetings. • We worked with the Royal Marsden Hospital to deliver training about sarcoma to 100 GPs. significantly increased the numbers of health professionals who successfully completed • We the Sarcoma UK-sponsored BMJ online module, ‘Lumps, Bumps and Sarcomas’ from 3,300 to 9,582 in 12 months. The module is the fourth most completed one during this period, with a 90% completion rate.

10,000 9000

9,552

8000 7000 6000 5000 4000 3000

3,300

2000 1000

findings of the Survey were • The presented in a written briefing to

0 Completed modules to end of March 2016

the National Cancer Director, Cally Palmer, and John Baron MP, Chair of the All Party Parliamentary Group on Cancer

Completed modules to end of March 2017

“ I recently had a case of sarcoma present as a painless lump so this was very helpful. I found this module through the sarcoma.org.uk website. Thank you for providing this.” GP

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Achievements and Performance – Priority 2

Seek answers through research

Grants awarded in 2016/2017:

What we said we would do:

Roger Wilson Research Award

1. Increase our investment into sarcoma scientific research to half a million pounds in a single year, focusing on basic science, clinical and quality of life research, and launch a new PhD studentship programme.

Can a holistic model of rehabilitation improve quality of life after treatment for lower extremity sarcoma? A pilot and feasibility study. Mr Craig Gerrand, Newcastle Upon Tyne Hospital NHS Foundation Trust £33,080 This pilot project will test if a more holistic approach to rehabilitation works for patients who need rehabilitation either immediately after treatment or more than six months later. This project will potentially improve rehabilitation for all sarcoma patients who have limb surgery.

2. Map all researchers and scientists in the UK with an interest in sarcoma. 3. Hold our first scientific symposium to answer the question “What causes sarcoma?” and identify research priorities for the next 10 years.

Development of a sarcoma-specific patient-reported outcome measure. Dr Rachel Taylor, University College London Hospitals £119,464 The aim of this project is to develop a sarcoma-specific Patient Reported Outcome Measure (S-PROM) using patient input and feedback. It also includes a strategy to incorporate this into clinical practice.

1. Increase investment - what we did: 2016/17, Sarcoma UK invested • In£491,582 into high quality scientific research into sarcoma, a significant increase from 2015/16 (£335,493).

This investment funded 10 research grants.

We received £1.5 million worth of high quality fundable applications for our allocated investment of £500,000.

Clinical Research Awards

2015/16

2016/17

£335,493

£491,582

We diversified our research grants • calls in 2016/17 into Clinical Research and Basic Science. launched our flagship PhD studentship programme - the Sayako Grace Robinson • We Studentship - a ten year research investment. The scheme is run as part of the Basic Science research grant call.

annual Roger Wilson Research Award invited applications for research into • Our Quality of Life.

Sayako Grace Robinson

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Roger Wilson

Magnetic Resonance guided Focused Ultrasound (MRgFUS) for the treatment of recurrent sarcomas Professor Lee Jeys, Royal Orthopaedic Hospital, Birmingham £24,800 This research will test the feasibility of using Magnetic Resonance Imaging (MRI) scans to treat locally recurring sarcomas. The technique directs high intensity ultrasound waves at tumours to cause thermal ablation. This non-invasive, day-case procedure may offer an alternative therapy for recurrent sarcomas. Does PET-MRI of myxofibrosarcoma improve the local staging of disease compared to standard MRI? A pilot and feasibility study. Dr George Petridis, Newcastle upon Tyne Hospital NHS Foundation Trust £19,212 Myxofibrosarcomas can infiltrate adjacent tissues, which can make the extent of the cancer difficult to assess for the surgeon planning removal. This research project plans to test whether using Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) will give an improved assessment of myxofibrosarcomas, and has potential to improve surgical outcomes for this group of patients. GeDDiS TransBio: Translational study to investigate prognostic and predictive immune biomarkers in soft tissue sarcoma (STS). Dr Sandra Strauss, University College London Hospitals £75,161 This project uses samples collected during the GeDDis clinical trial to see if there are any markers which might response to current and new immune therapies that are entering clinical studies.

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Achievements and Performance – Priority 2

Seek answers through research

Grants awarded in 2016/2017: Basic Science Awards

Grants awarded in 2016/2017:

Unravelling the epigenetic regulation of brachyury to identify new targets for the treatment of Chordoma. Professor Adrienne Flanagan, Royal National Orthopaedic Hospital, London £25,000

Sayako Grace Robinson PhD Studentship

The protein brachyury has a known role in Chordoma. Lab experiments have shown that if this protein is not there, the Chordoma cell dies. This project will look at how using drugs to switch off the gene that makes brachyury affects Chordoma cells growth. This research could lead to a clinical trial for new treatment for Chordoma.

Defining the mechanisms of pazopanib and regorafenib resistance in soft tissue sarcoma. Dr Paul Huang, The Institute of Cancer Research, London £119,960

Combination immunotherapy with immune checkpoint inhibition and oncolytic vaccinia virus delivered by isolated limb perfusion (ILP) to target metastases in extremity soft-tissue sarcoma. Mr Andrew Hayes, The Institute of Cancer Research, London £24,905

This project aims to discover how the body develops resistance to two chemotherapy drugs (pazopanib and regorafenib) used in the treatment of soft tissue sarcoma. Using tumour samples collected from patients treated with these drugs, a lab-based model will be made of the cells. This model will be used to investigate the biological processes of how resistance occurs. This research could help doctors test patients before chemotherapy to check they will respond to the treatment. It will also increase knowledge of how to overcome drug resistance in sarcoma.

Isolated limb perfusion (ILP) is a surgical technique used to administer chemotherapy. The limb is isolated from the rest of the body and chemotherapy given directly to it. It is used in cases where the tumour is large or the limb has had previous surgery. This project will investigate how adding a cancer killing virus to the ILP treatment affects the immune system and how combining this with other treatments may affect the growth and spread of sarcoma.

Trustee Prof Ian Judson and Paul Huang

Sarcomas fuelled by the squeeze – Does the Hippo release the pressure? Dr Carsten Hansen, University of Edinburgh £25,000 This project looks at the difference in the pressure of cells inside an osteosarcoma tumour compared to cells outside. Sarcomas with a high internal pressure are more able to spread. The research will look at the causes of the pressure difference and how this affects the growth and spread of osteosarcoma.

Development of a gene signature as a biomarker of tumour hypoxia in soft tissue sarcoma. Professor Catharine West, University of Manchester £25,000 Cancer cells have lower oxygen levels, known as hypoxia. This project looks at using genetic markers to identify when sarcoma cells are hypoxic. This knowledge will then be used to test drugs that may kill hypoxic sarcoma cells. This research has the potential to test which patients may benefit from treatment which targets hypoxia, and may give a better outcome for patients with soft tissue sarcoma.

We continued to fund previous research commitments – see www.sarcoma.org.uk for details. 12

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Achievements and Performance – Priority 2

Achievements and Performance – Priority 3

Seek answers through research

Support the sarcoma community and provide information

2. Map researchers - what we did:

•

We identified all UK researchers who had published in the field of sarcoma.

What we said we would do: 1. Expand our national Support Line and support services. 2. Expand the range and distribution of our patient information.

3. Sarcoma Research Symposium - what we did:

first Sarcoma Research Symposium focused on basic science and was attended • Our by over 70 delegates including scientists, researchers and clinicians, and featured high profile speakers (Acknowledgements page 20).

a poster display and competition featuring 16 research projects from junior • Held researchers, providing an opportunity to showcase their research. • Identified Research Priorities (Basic Science):

1. Expand our support services - what we did:

Support Line was open for 20 hours a week, responding to questions from • The patients, family members, friends, and health professionals by phone and email. 1 April 2016 to 31 March 2017, the Support Line had 1044 contacts, from 411 • From individuals. The average call length is 28 minutes. capacity of the Support Line was expanded in July 2016 with the recruitment of a • The second sarcoma nurse specialist as Support Line lead. evaluation of the service was carried out in • An2017internal Sarcoma to assess impact and develop the service. Support Line 0808 801 0401 continue to support and financially assist 14 regional • We sarcoma support groups throughout the UK, including a

To work together - to create a strong and dynamic community

To invest in sarcoma researchers of the future - bringing in fresh ideas, innovation and energy

To create meaningful scientific models of sarcoma - to separate what’s value from what’s ‘noise’

To develop a national sarcoma research strategy - that sets out how sarcoma patients participate in research; and encourages centralised workflows for the collection and use of samples and data

4. What we did – other:

International Sarcoma Kindred Study (UK arm funded by Sarcoma UK) was the focus of a • The paper published in Lancet Oncology by Professor Ian Judson, and was highlighted by the BBC and in The Guardian.

looking into potential treatments for Chordoma, led by Professor Adrienne Flanagan • Aandproject part-funded by Sarcoma UK, has resulted in a clinical trial in 2017 sponsored by Boehringer Ingelheim.

our funded research yielded the following outputs: • In– 112016-17, oral presentations at UK and international scientific meetings and conferences – 9 poster presentations at UK and international scientific meetings and conferences – 5 publications – 1 clinical trial

new support group for desmoid-type fibromatosis.

supportline@sarcoma.org.uk

provided face-to-face support to 238 patients at eight patient support events and • We two wellness days.

2. Expand the range and distribution of our information - what we did:

5,133 patient information booklets and factsheets to 47 specialist centres, • Distributed 52 treatment centres and 85 information centres, including new outlets identified via a mapping exercise.

our booklets and factsheets available digitally, resulting in 5,980 downloads of • Made booklets and factsheets. six new information products including Understanding desmoid-type • Produced fibromatosis; Giant cell tumour of the bone; and Lymphoedema & sarcoma. in partnership with The Christie • Worked Hospital, Manchester to produce a A Sarcoma UK factsheet

produced by the Information and Support Team

factsheet on Proton Beam Therapy, which will be distributed by The Christie team in the PBT Unit from 2018.

Proton beam therapy Certain types of sarcoma can be treated using a type of radiotherapy called proton beam therapy (PBT). This therapy is not currently available in the UK. Proton beam therapy services are expected to start in the UK in 2018. NHS commissioned services will be initially delivered at The Christie Hospital in Manchester and later also at University College London Hospital. Since 2008 the NHS has been paying for selected sarcoma patients to have proton beam treatment in the USA or Europe. They will continue to do so until both UK sites are fully operational. This factsheet explains more about PBT including who is eligible for this treatment and how you can access this treatment overseas.

What is radiotherapy? Radiotherapy is a type of cancer treatment that uses high-energy radiation beams to destroy cancer cells. It can be used to treat both bone and soft tissue sarcomas before, after or instead of surgery. When used before surgery it aims to reduce the size of the tumour, or treat the margins of the tumour to make surgery more effective. In some cases, radiotherapy is used after surgery. In this case, the aim is to kill off any local cancer cells which may remain in the area of the tumour.

What is PBT? Proton beam therapy is a different type of radiotherapy that uses high-energy proton beams rather than high-energy radiation beams to deliver a dose of radiotherapy. It can be used

to treat different types of cancer including some types of sarcoma.

Which sarcoma patients might benefit from proton beam therapy? Children or young people can benefit from PBT as radiation can sometimes damage their developing organs. Radiotherapy delivered to healthy tissue in children and teenagers can sometimes result in long term effects. Depending on where the sarcoma is and the radiation dose needed, these may include problems with: Growth IQ Development through puberty Hormone deficiencies Fertility Small increased risk of developing a second cancer

• • • • • •

Adults with sarcoma in parts of the body which are hard to treat could also benefit from PBT. These areas include: Spine Base of the skull Head and neck region Pelvis

• • • •

The accuracy of PBT means a higher dose of radiation can be given to a specific area, reducing radiation dose to the normal surrounding tissues.

What are the benefits of PBT? The main advantage of PBT is in reducing longterm side-effects of radiotherapy rather than

sarcoma.org.uk

Sarcoma UK Report of the trustees for the year ended 31 March 2017

A Sarcoma UK factsheet produced by the Information and Support Team

Giant cell tumours of the bone What is GCT? Giant cell tumours (GCT) are benign (noncancerous) tumours that develop in the bone. They mostly occur in the long bones found in the arms and legs. They are always found at the end of the bone next to the joint. Although they are benign, GCT can grow fast and damage the affected bone and spread to the soft tissue around it. GCT mostly affects people between the ages of 20 and 30 years old. It is also more common in women. We do not know why they arise.

Signs and symptoms The most common symptoms of GCT are: Pain Swelling in the area of the tumour Fractures in the bone caused by bone weakness

• • •

Who will treat me? People with a suspected GCT should be referred to a specialist sarcoma team for diagnosis and treatment. There are five national bone sarcoma centres in England and Wales where all bone sarcoma patients should be treated. These are located in Newcastle, Manchester & Oswestry, Birmingham, Oxford and London. People in Northern Ireland will be treated in Belfast. People in Scotland will

be treated in Glasgow, Edinburgh, Aberdeen, Dundee and Inverness. As there are only a small number of centres that treat GCT, you may have to travel some distance for your treatment. Some treatments like radiotherapy or chemotherapy may be given in your local hospital under the supervision of the specialist sarcoma centre. Your case will be managed by a team of experts from a wide range of health care professions called a multidisciplinary team (MDT). Your MDT will include your key worker or sarcoma clinical nurse specialist, surgeon and other healthcare professionals involved in your care.

How is GCT diagnosed? A specialist doctor will diagnose GCT through a series of tests. These may include: Physical examination A scan – taking pictures of the inside of the body using x-ray, bone scan, CT or MRI A biopsy – taking and testing a tissue sample

• • •

You may also have a chest x ray to look for any cells that may have spread to the lungs. This is extremely rare in GCT patients.

sarcoma.org.uk

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Achievements and Performance – Priority 4

Build a strong charity In a challenging fundraising environment, we place more emphasis than ever on Sarcoma UK’s ethos of personalised support for fundraisers, attentive stewardship of donors, and positive messages in our appeals. This approach, and our strategy to diversify income streams, seems to be paying dividends: our income increased by 14% this year.

UK’s community of runners, bakers, cyclists, skydivers, gig organisers, knitters • Sarcoma and Tough Mudders had another magnificent year. Thanks to their efforts, JustGiving named us as one of their top 100 charities and we learned that the average value of a page for Sarcoma UK is approximately three times that of pages across the platform. To everyone who took up a challenge or fundraised in their community, we offer our heartfelt thanks; we simply couldn’t do what we do without your energy and enthusiasm. implementation of our strategy to diversify income streams • The continued in 2016/17 with the appointment at the start of the year of a Fundraising Officer with responsibility for Trusts and Foundations. This stream has already begun to expand, and represents 12% of our total income compared to 3% last year. Legacy income – always challenging to predict – fell from last year, but following the launch of a new web page we received notification from more supporters that they have included a donation to Sarcoma UK in their will.

fledgling Major Gifts programme developed thanks to the reception at 10 Downing Street in • Our November, which enabled us to strengthen relationships with several key individuals. This year, we also received the first instalment of a transformational philanthropic gift to fund a series of PhD studentships in sarcoma basic science, named in memory of Sayako Grace Robinson. Significant contributions to our income also came from corporate supporters, including 10 Downing Street and David Wilson Homes.

Fundraising case studies Gina Long first contacted Sarcoma UK after her family was touched by sarcoma. A passionate charity supporter, she was awarded an MBE in 2016 in recognition of 35 years of fundraising for good causes. She told us she wanted to use her vast experience of gala events and online auctions to raise money to fight sarcoma, and we were delighted that she chose us as a beneficiary of her Secret Garden Ball and Ultimate Charity Auction, which included ‘money can’t buy’ lots such as a training session with Paralympic gold medallist and Sarcoma UK patron Richard Whitehead, a VIP Manchester United experience and a luxury catamaran trip around the British Virgin Islands. At Christmas, Gina and her husband Andrew visited our office to hear how Sarcoma UK supports people affected by sarcoma, and to present a cheque for over £57,000. Every year, we are inundated with applications to run the London Marathon, and deciding how to allocate our places becomes more and more difficult. But when James Read proposed running in a giant golf ball costume, we knew we couldn’t refuse! James’s wife Sarah had recently undergone major surgery, having been diagnosed with sarcoma at the age of 28, only a few months after their honeymoon. James said: “After learning that only 53% of the public have heard of sarcoma and only 26% know that sarcoma is a cancer, I knew I had to take action. Dressing up as a giant golf ball would have helped raise sarcoma awareness along the route and prompted the public to go to their GP if they have a lump the size of a golf ball.” Over the last few years, James has raised a total of £16,250 and continues to take on sporting challenges for Sarcoma UK.

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Future Plans

Achievements and Performance – Priority 4

Build a strong charity

Investment income 1%

Gift Aid 8%

Legacies 1% Corporate donations 9% Trusts & foundations 12%

How we raise our money

Major giving 9%

General donations 60%

Strategic Priorities 1. Initiate change to raise awareness of sarcoma and improve standards of treatment and care. 2. Seek answers through research. 3. Support the sarcoma community and provide information. 4. Build a strong charity.

2017/18 We will:

two research grant calls - basic science and clinical research, and • Run continue our level of investment into high quality sarcoma research. a mass participation event for the sarcoma community during • Launch Sarcoma Awareness Week. sarcoma patients and their families with new ways to access our • Provide support and information services. full compliance with new charity fundraising regulations and data • Ensure protection legislation in a changing external environment. .

Raising funds 20%

Awareness & education 22%

How we spend your money Information & support 13%

Research 45%

The Christie in Manchester will be the venue for a brand new proton beam therapy centre, due to treat its first patients in 2018.

The above activities include 16% support costs and 2% governance costs, which have been re-allocated to each activity (see notes to financial statements).

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Acknowledgements

Patron

Founder Roger Wilson CBE

Programme Committee

Research Advisory Committee

Prof Adrienne Flanagan Professor of Musculoskeletal Pathology, University College London

Professor Penella Woll (Chair) BMedSci, MBBS, PhD, FRCP Professor of Medical Oncology, University of Sheffield

Mr Sam Patton FRCS (Tr & Orth), FRCSEd, MB ChB Consultant Orthopaedic Specialist Surgeon, Royal Infirmary of Edinburgh

Dr Sara Booth MD FRCP FRCPE Honorary Consultant, Associate Lecturer, University of Cambridge Honorary Senior Lecturer at the Department of Palliative Care and Policy, King’s College London

Professor Janet Shipley PhD Head of the Division of Molecular Pathology, The Institute of Cancer Research

Dr Bernadette Brennan BSc, MBChB, MRCP (UK), FRCPCH, MD Consultant Paediatric Oncologist, Royal Manchester Children’s Hospital Mr Paul Cool MD MMedSc (Res) FRCS (Ed) FRCS (Orth) Consultant Orthopaedic & Oncological Surgeon, The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry Mr Anant Desai BA MA MBBS MD FRCS Consultant General Surgeon, Queen Elizabeth Hospital, Birmingham Dr Sinclair Dundas PhD, MBChB, FRCPath Consultant Pathologist, Aberdeen Royal Infirmary Professor Adrienne Flanagan MB, BCh, BAO, PhD, LRCPI, LRCSI, FRCPath, FMedSci Professor of Musculoskeletal Pathology, University College London Consultant Pathologist/Clinical Lead, Royal National Orthopaedic Hospital Professor Ted Hupp PhD Principal Investigator and Professor of Cancer Research, University of Edinburgh

Research Symposium

Richard Whitehead MBE

Sarcoma UK Acknowledgements for the year ended 31 March 2017

Dr Karen Sisley BSc, PhD Senior Lecturer, University of Sheffield Dr James Spicer MRCP, PhD, FCRP Consultant in Medical Oncology, Guy’s and St Thomas’ Hospitals Co-lead of the King’s Experimental Cancer Medicine Centre, King’s College London Dr Sandra Strauss BA, MBBS, MRCP (UK) PhD Consultant Medical Oncologist, University College Hospitals London Dr Neil Vargesson BSc, PhD, FHEA Senior Lecturer, University of Aberdeen Professor Galina Velikova BMBS, RCP, PhD Chair of Psychosocial and Medical Oncology, University of Leeds Dr Paula Wilson BSc, MBChB, MRCP (UK), FRCR Consultant in Clinical Oncology, University Hospitals Bristol Dr Jayne Wood MBBS FRCP BSc PgDip Consultant in Palliative Medicine and Clinical Lead, Royal Marsden and Royal Brompton Hospitals London

Professor Janet Shipley Head of the Division of Molecular Pathology, The Institute of Cancer Research Professor Ted Hupp Principal Investigator and Professor of Cancer Research, University of Edinburgh Dr Hugh Robinson Senior Lecturer, University of Cambridge

Speakers Professor Adrienne Flanagan (Chair) Professor of Musculoskeletal Pathology, University College London Professor Gerard Evan Sir William Dunn Professor of Biochemistry, University of Cambridge Professor David Thomas NHMRC Senior Research Fellow; Director of the Kinghorn Cancer Centre; Head of the Cancer Division at the Garvan Institute of Medical Research, Sydney Dr Sam Behjati Wellcome Trust Sanger Institute Intermediate Clinical Fellow Dr Clare Turnbull Senior Researcher, The Institute of Cancer Research, London Professor Tony Carr Director, Genome Damage and Stability Centre, University of Sussex Dr Paul Huang Team Leader, The Institute of Cancer Research, London Professor Ted Hupp Professor of Cancer Research, University of Edinburgh Professor Janet Shipley Head of the Division of Molecular Pathology, The Institute of Cancer Research, London Dr Andrea Siodmok Head of the Policy Lab, Cabinet Office Professor Peter Rigby Former Chief Executive Officer, The Institute of Cancer Research, London

Sarcoma UK Acknowledgements for the year ended 31 March 2017

Reference and Administrative Details

Acknowledgements

A huge thank-you to all our major donors Street • 10TheDowning • The Analyst Foundation • DavidBoom Wilson Homes South West • The Edith • FoundationLilian Harrison 2000 • The GeeWizz Charitable Trust

Corporate donors

Bank plc • Barclays Management Ltd • Beazley Lease2Buy • MBNA Ltd Cars •

Company number

7487432 (Limited by guarantee in England and Wales)

Sarcoma Awareness • Jessica’s Kilpatrick Fraser Charitable Trust • The The McAlpine Foundation • GwenRobert Robinson • The RoyOwen Thompson Trust • The Thompson FamilyCharitable Charitable Trust •

Charity number

England and Wales (1139869) Scotland (SC044260)

Registered Office

49-51 East Road London N1 6AH

Trustees

Trustees, who are also directors under company law, who serviced during the year and up to the date of this report were as follows:

Academy Glasgow • O2 Network UK Ltd • Omidyar Penningtons Manches •

Karen Delin (Chair) Dr Jane Barrett (term of office ended October 2016) Sarah Bartholomew Andy Eckles Professor Rob Grimer Leigh Hibberdine Ian Hughes Professor Ian Judson Sharon Reid Helen Stradling (resigned June 2016) Johanna Vass Dr Jeff White Sam Whittam Glyn Wilmshurst Patron Richard Whitehead MBE

Gifts in kind

• Touchline – design of a Sarcoma UK report and hosting a supporter reception

Group Funds

• • • • • • • •

The Adam Jones Fund The Amy Westlake Fund The Chris Martin Fund The Dave Thompson Fund The Derek Watkins Fund 007 Hope’s Fund The James Hessey Fund The Leigh Gaskin Fund

Richard Sumner Fund • The Sandie’s Stars Fund • The The Darling Fund • The Stephanie Allison Tribute Fund • The Terry Tom Eckles Fund • The Tom McMahon • The ULegend Fund Fund •

Legacies We recognise the deeply personal decisions involved when making a will, and express our unending gratitude to the following supporters from whose wills we received a gift in 2016/17. Waters • Bernadette • Elizabeth Gale

Crellin • Virginia • Louise Garbett

Individuals who have provided professional support The following people have provided valuable professional support and advice to Sarcoma UK on a pro-bono basis. Rachel Billsberry-Grass (Consultant, CauseWorks) Mark Gould (Director, The Systems Management Company) Katie Heyward (Head of Trust Fundraising, Action Medical Research)

• • •

Chief Executive

Lindsey Bennister

Company Secretary

Karen Wines

Bankers

CAF Bank Ltd, 25 Kings Hill, Avenue Kings Hill, West Mailing, Kent ME19 4JQ

Lloyds TSB, National Clubs & Charities, PO Box 1000 BX1 1LY

Solicitors

Brahams Dutt Badrick French LLP, 24 Monument Street, London EC3R 8AJ

Auditors

Sayer Vincent LLP Chartered accountants and statutory auditors Invicta House 108 – 114 Golden Lane London EC1Y 0TL

Other

Andrea Siodmok (Head of the Policy Lab, Cabinet Office) and the staff at The Cabinet • DrOffice Policy Lab. The staff 10 Downing Street for support throughout our Charity of the Year partnership. • Paul Whiteof(Peak Magda Archer (artist); and Richard Whitehead MBE (Paralympian and • Sarcoma UK Patron)Venues); who donated auction lots for the Ultimate Charity Auction.

Sarcoma UK Acknowledgements for the year ended 31 March 2017

Sarcoma UK Reference and administrative details for the year ended 31 March 2017

Governance, Structure and Management

Legal Entity

Sarcoma UK is a charity registered in England and Wales with the Charity Commission on 17 January 2011, and registered as a charity in Scotland on 12 September 2013. Its governing documents are its memorandum and articles of association. Sarcoma UK is also a company limited by guarantee incorporated with Companies House on 10 January 2011. Sarcoma UK is sole corporate Trustee of former charity The Sarcoma Trust.

Charitable Objectives

The objectives of the charity are to promote and protect the physical and mental health of patients with bone and soft tissue sarcomas in the United Kingdom through the provision of information, support, education and practical advice to them, their families and their carers; the relief of sickness and the preservation of health in particular by promoting and supporting research with the publication of the useful results thereof and the development of more effective treatment and care for patients with bone and soft tissue sarcomas; to advance the education of the general public in all areas relating to sarcoma.

Board of Trustees 2016/17 Karen Delin – Chair Karen has over 20 years’ experience in palliative care nursing. Diagnosed with a gynaecological sarcoma in 2006, Karen established and continues to organise the London Sarcoma Support Group as well as being a founder trustee of Sarcoma UK.

Sarah Bartholomew Sarah is former Head of Events & Visits at 10 Downing Street, having worked for both the current and previous Prime Minister. Sarah was a colleague of Chris Martin at 10 Downing Street and she led their working group during our Charity of the Year partnership in 2016. Sarah is now a Director at the newly formed Commonwealth Summit Unit, part of the Cabinet Office.

Andy Eckles – Trustee with special interest in finance Andy has 30 years’ experience in finance, as both an auditor and currently as Group Financial Controller at Huntswood, a company that provides specialist resourcing and consultancy services. Andy’s son, Tom, passed away from Ewing’s sarcoma in September 2015.

Professor Rob Grimer Rob is a (retired) Professor of Orthopaedic Oncology at the Royal Orthopaedic Hospital, Birmingham. During his long career in sarcoma, he helped pioneer the use of extendable prostheses and new surgical techniques such as irradiation and re-implantation of bone to treat sarcoma. He is a founding member of the British Sarcoma Group.

Leigh Hibberdine Leigh works in events management and became involved with Sarcoma UK when her daughter was diagnosed in 2009 with paediatric wild-type GIST (gastro-intestinal stromal tumour).

Professor Ian Judson Ian has been treating patients with sarcoma for 25 years as Head of the Sarcoma Unit at the Royal Marsden until his retirement in 2016. He has conducted many clinical trials in this area, and was a founder member of the British Sarcoma Group, and President until 2015.

Sharon Reid Sharon is a former Executive Director and Chief Operating Officer at Edelman, the world’s largest PR agency, and has worked in communications for the last 18 years.

Johanna Vass Jo is a Sarcoma Advanced Nurse Practitioner, the lead for sarcoma nursing services and a key member of the South Wales Sarcoma Multi-Disciplinary Team. She was the first sarcoma specialist nurse to be appointed in South Wales in 2012.

Dr Jeff White Jeff is a consultant medical oncologist working in sarcoma at the Beatson West of Scotland Cancer Centre, and former National Lead Clinician for the Scottish Sarcoma Network.

Sam Whittam Sam is a barrister working principally in the area of child protection and was called to the bar in 1995. In 2009, Sam lost her friend to sarcoma.

Glyn Wilmshurst Glyn co-founded the communications agency Touchline, which produces the publications, websites and branding of several governments as well as various international arts, trade, travel and sports organisations. Glyn was diagnosed with a myxoid liposarcoma in December 2010.

Sub-Committees

Responsibility for HR and staffing issues is delegated to the HR Sub-Committee who make recommendations to the Board of Trustees, including staff remuneration. Members 2016/17:

Hibberdine • Leigh Sam Whittam • Glyn Wilmshurst •

Responsibility for the renewal of tenure, recruitment and appointment of trustees is delegated to the Nominations Sub-Committee who make recommendations to the Board of Trustees. Members 2016/17:

Delin • Karen Ian Hughes • Dr Jeff White •

Ian Hughes Ian is the owner of SILO Consulting Ltd, based in York. Ian was diagnosed with leiomyosarcoma in 2010.

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Governance, Structure and Management

Trustee Appointment and Induction

Sarcoma UK places a high value on having an informed and skilled Board of Trustees which guides the charity to achieve its ambitious goals. Trustees serve a three-year term, after which they are eligible for re-election for a further three years. New trustees are recruited in various ways, according to the skills sought by the Board. Vacancies are advertised in national charity media; through professional networks; and via the charity’s website and networks. Potential trustees are invited to submit a formal application and attend an interview with the Nominations Sub-Committee. All trustees receive the Trustee Handbook, setting out the role and responsibilities of Sarcoma UK trustees, including the charity’s policies and procedures relating to governance. A Register of Trustees’ Interests is in place and updated annually. All new trustees receive the governing document, strategy and business plan, published accounts and minutes of previous Board of Trustee meetings, Trustee Handbook, as well as Charity Commission guidance on effective governance. A formal induction programme is in place, where trustees spend time with the Chief Executive and the Senior Management Team. Trustees are subscribed to Governance publication and are encouraged to attend training and other events for charity trustees.

Organisational Structure

The Board of Trustees sets the strategic direction of Sarcoma UK and approves the main policies of the charity. It appoints and directs the Chief Executive, monitors performance and identifies and manages the major risks facing the charity. The Board meets four times a year. The Board delegates responsibility for the running of the charity to the Chief Executive with clearly communicated and recorded executive limits. The Chief Executive is responsible and accountable for achieving Sarcoma UK’s strategic objectives and delivering the annual business plan. A Senior Management Team is in place to support the Chief Executive, providing leadership across key areas of the charity’s work, and ensuring delivery of the charity’s day-to-day work. Sarcoma UK’s Senior Management Team in 2016/17 consisted of: Executive • Chief Director • Communications of Finance & Resources • Director of Fundraising • Director • Director of Research, Support & Information

Sarcoma UK has a policy for reviewing staff salaries, set out in the Staff Handbook. Staff salaries are reviewed annually by the Board of Trustees HR Sub-Committee, on behalf of the Board of Trustees, and benchmarked against voluntary sector pay surveys and inflation. The remuneration of senior management is covered under this policy.

Volunteers

The trustees recognise the valuable contribution made by volunteers to Sarcoma UK and wish to record their gratitude for this commitment. These include members of Sarcoma UK’s Research Advisory Committee; sarcoma support group leaders; Sarcoma UK’s Information Review Panel; individuals and families who have provided their stories for use as case studies; everyone who has undertaken fundraising and awareness-raising in their communities; and everyone who has set up information stands and cheering stations at events and challenges. In accordance with accepted practice, no amounts are included in the financial statements to reflect the value of work undertaken by volunteers.

Risk Assessment

Sarcoma UK has a risk assessment model in place, which is reviewed regularly by the Senior Management Team and trustees. This model sets out the processes for identifying major strategic risks, assessing their likely impact and, where appropriate, the measures that need to be implemented to mitigate the risks. In our risk assessment model, risks are categorised under the following headings: Governance, Financial, Operational, Environmental and External Factors, Compliance Risk, and Charitable Objectives. The most significant current risk to the charity has been identified as the impact of the external environment on fundraising, in particular: 1. New fundraising regulations 2. New data protection regulations 3. Public confidence in charities 4. Uncertainty around Britain’s withdrawal from the EU and the possible economic impact To manage this risk, the following actions will be incorporated into the risk model: 1. Investment into new fundraising streams to spread the risk and establish greater diversity in fundraising sources. 2. Training and knowledge-building opportunities for trustees and staff to ensure full understanding of the new regulations. 3. An objective in the 2017/18 business plan to achieve full compliance with new fundraising and data protection regulations. 4. Robust monitoring of monthly management accounts to identify changes in income patterns as early as possible. The risk model has been reviewed by the trustees and they are satisfied that appropriate systems are in place to mitigate major risks.

The total number of staff employed at 31 March 2017 was 13 (including three part-time). The trustees are grateful to the staff team for the outstanding work they do on behalf of people affected by sarcoma.

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Financial Review

Grant Making Policy

Our research grants programme for sarcoma involves annual calls for proposals which are publicised to the UK sarcoma research community, in particular sarcoma active researchers and UK Higher Education Institutes. Applications submitted undergo a rigorous peer review process to identify the best quality sarcoma research projects in centres of excellence across the UK. Our Research Advisory Committee considers all peer reviews and makes recommendations for funding to the Board of Trustees, who approve the final grants. Sarcoma UK is a member of the Association of Medical Research Charities (AMRC) and is fully compliant with their practices. Our Principles of Peer Review Policy is published and all applicants are made aware of it. We also publish our Conflicts of Interest policy, whereby all members of the Research Advisory Committee are required to provide an annual declaration of potential conflicts of interest. The policy also sets out the conditions for automatic exclusion from participation in funding decisions for members who have conflicts of interest, and this policy is implemented rigorously at meetings. Our research strategy states that no area of research is given greater priority over any other within a call. We always award on the basis of the scientific quality of the proposed studies. Clinical research projects must be patient focused. We will support both people and projects, and will provide funding for pump-priming research to support the development of ideas. We wish to increase the sum total of sarcoma research in the UK and remain flexible in our approach towards funding and research partnerships.

Public Benefit

The trustees have referred to the guidance contained in the Charity Commission’s general guidance on public benefit when reviewing the charity’s aims and objectives and in planning its future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives that have been set.

Working with Others

Sarcoma UK recognises that progress towards our goals is maximised when working collaboratively with others who share an interest in improving the lives of people affected by sarcoma. As the only UK charity focusing on all types of sarcoma, we aim to work collaboratively with the whole sarcoma community to achieve our vision for the future. In March 2017, the trustees approved guiding principles for Sarcoma UK’s collaboration with other organisations to ensure maximum impact for our supporters. In 2016/17, Sarcoma UK had collaborations with the Association of Medical Research Charities (AMRC); BMJ Learning; The Boom Foundation (Northern Ireland); British Sarcoma Group; Cancer 52; The Christie Hospital; The Good Grief Trust; GIST Support UK; Maggie’s Centres; National Cancer Research Institute (NCRI) sarcoma clinical studies group; NCRI James Lind Alliance Priority Setting Partnership – Living With and Beyond Cancer steering group; National Institute of Health and Care Excellence (NICE); National Sarcoma Forum (of specialist nurses); NHS England; Sarcoma Patients EuroNet; The Royal Marsden Hospital; Shine Cancer Support; the Scottish Sarcoma Network; and the network of sarcoma specialist centres – bone and soft tissue – in England, Wales and Northern Ireland.

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Income

Sarcoma UK has made excellent progress against its objectives for the year, successfully raising £1,369,014, an increase of 14% from the previous year (2016: £1,202,498), which exceeded our income forecast for the year. This is the direct result of the investment made into our fundraising team during the year and shows early evidence of the future potential in our new fundraising programmes, in particular Trusts and Foundations, Legacies, and Major Gifts.

Expenditure

Total expenditure increased by 28% to £1,396,746 (2016: £1,094,574). Expenditure on charitable activities increased by 29% to £1,118,488 (2016: £867,426). This reflects the significant increase in investment into research this year, as well as the ongoing level of commitment to our charitable objectives of Information and Support, and Awareness and Education. We strive to keep the costs of raising money to a minimum. There has been an increase of 23% in the cost of raising funds, which has directly resulted in an increase in our level of income and is building a secure funding base for the future. This year for every £1 spent on fundraising £4.90 was raised (2016: £5.26). There was a planned deficit of £27,732 (2016: surplus £107,924). This represents expenditure of restricted funds carried forward from the previous year and decreases total charity funds to £952,661 (2016: £980,393), of which £7,546 are restricted. The reserves policy is discussed below. The trustees wish to thank all donors for their invaluable support during the year, which is helping Sarcoma UK transform the lives of everyone affected by sarcoma.

Reserves Policy

The Board of Trustees reviewed and changed the reserves policy in December 2016 with the aim of maintaining reserves at a level which equates to approximately six months of overhead costs. The total funds of the charity at 31 March 2017 were £952,661 of which £7,546 are restricted. This leaves a balance of £945,115 as unrestricted funds. The trustees have agreed to designate £500,000 of these unrestricted funds to research grants in 2017/18, leaving a balance of £445,115. The level of reserves is equivalent to over six months of overhead costs. This is approximately £380,000 for the forthcoming year, which will ensure uninterrupted services and delivery of our charitable activities. The reserves policy will be reviewed in 2017/18, to ensure it is adequate for the charity’s future operational needs.

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Statement of Responsibilities of the Trustees

The trustees (who are also directors of Sarcoma UK for the purposes of company law) are responsible for preparing the trustees’ annual report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that period. In preparing these financial statements, the trustees are required to:

suitable accounting policies and then apply them consistently • Select the methods and principles in the Charities SORP • Observe judgements and estimates that are reasonable and prudent • Make whether applicable UK Accounting Standards and statements of recommended • State practice have been followed, subject to any material departures disclosed and explained in the financial statements

the financial statements on the going concern basis unless it is inappropriate to • Prepare presume that the charity will continue in operation The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. In so far as the trustees are aware:

is no relevant audit information of which the charitable company’s auditor is unaware • There trustees have taken all steps that they ought to have taken to make themselves aware of • The any relevant audit information and to establish that the auditor is aware of that information

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. The total number of such guarantees at 31 March 2017 was 12 (2016:10). The trustees are members of the charity but this entitles them only to voting rights. The trustees have no beneficial interest in the charity.

Auditor

Sayer Vincent LLP was re-appointed as the charitable company’s auditor during the year and has expressed its willingness to continue in that capacity. The trustees’ annual report has been approved by the trustees on 3 October 2017 and signed on their behalf by Karen Delin Chair of Trustees

Sarcoma UK Report of the trustees for the year ended 31 March 2017

Independent Auditor’s Report to the Members of Sarcoma UK

Opinion

We have audited the financial statements of Sarcoma UK (the ‘charitable company’) for the year ended 31 March 2017 which comprise the statement of financial activities, balance sheet, statement of cash flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ (United Kingdom Generally Accepted Accounting Practice). In our opinion, the financial statements:

a true and fair view of the state of the charitable company’s affairs as at 31 March • Give 2017 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended

been properly prepared in accordance with United Kingdom Generally Accepted • Have Accounting Practice been prepared in accordance with the requirements of the Companies Act 2006, the • Have Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended)

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

trustees’ use of the going concern basis of accounting in the preparation of the financial • The statements is not appropriate; or trustees have not disclosed in the financial statements any identified material • The uncertainties that may cast significant doubt about the charitable company’s ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The other information comprises the information included in the trustees’ annual report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material Independent auditor’s report to the members of Sarcoma UK

Independent Auditor’s Report to the Members of Sarcoma UK

misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006 In our opinion, based on the work undertaken in the course of the audit:

information given in the trustees’ annual report, for the financial year for which the • The financial statements are prepared is consistent with the financial statements trustees’ annual report, has been prepared in accordance with applicable legal • The requirements

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees’ annual report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion: accounting records have not been kept, or returns adequate for our audit have • Adequate not been received from branches not visited by us; or financial statements are not in agreement with the accounting records and returns; • The or disclosures of trustees’ remuneration specified by law are not made; or • Certain have not received all the information and explanations we require for our audit; or • We trustees were not entitled to take advantage of the small companies’ exemptions • The in preparing the trustees’ annual report and from the requirement to prepare a strategic

the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed. We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. Noelia Serrano (Senior statutory auditor) 5th October 2017 for and on behalf of Sayer Vincent LLP, Statutory Auditor Invicta House, 108-114 Golden Lane, LONDON, EC1Y 0TL Sayer Vincent LLP is eligible to act as auditor in terms of section 1212 of the Companies Act 2006.

report.

Responsibilities of trustees

As explained more fully in the statement of trustees’ responsibilities set out in the trustees’ annual report, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

This report is made solely to the charitable company’s members as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005. Our audit work has been undertaken so that we might state to

Independent auditor’s report to the members of Sarcoma UK

Sarcoma UK Financial statements for the year ended 31 March 2017

Financial Statements

Statement of financial activities

(Incorporating an income expenditure account) Statement ofand Financial Activities

Balance sheetSheet Balance

(Incorporating an income and2017 expenditure account) For the year ended 31 March For the year ended 31 March 2017 Note

Unrestricted £

As atthe 31 year March 201731 March 2017 For ended

Restricted £

2017 Total £

2016 Total £

Income from: Donations and legacies

Other trading activities Investments Total Income

1,111,707

251,129

1,362,836

1,192,901

3,000

6,178

6,597

1,117,885

251,129

1,369,014

1,202,498

Expenditure on: 4

276,821

1,437

278,258

227,148

Research

356,110

277,585

633,695

440,401

Information and support

172,253

2,281

174,534

178,652

Awareness and education

308,924

1,335

310,259

248,373

1,114,108

282,638

1,396,746

1,094,574

3,777

(31,509)

(27,732)

107,924

Raising funds Charitable activities

Total expenditure Net income / (expenditure) and net movement in funds for the year

Reconciliation of funds: Total funds brought forward

941,338

39,055

980,393

872,469

Total funds carried forward

945,115

7,546

952,661

980,393

All of the above results are derived from continuing activities. There were no other recognised All of the above results are derived from continuing activities. There were no other recognised gains gains or losses other than those stated above. Movements in funds are disclosed in Note 16 to or losses other than those stated above. Movements in funds are disclosed in Note 16 to the financial the financial statements. statements.

Note Fixed assets: Tangible assets Current assets: Debtors Short term deposits Cash at bank and in hand Liabilities: Creditors: amounts falling due within one year

10,228

11 12

2017 £

2016 £ 15,646

198,282 207,916 1,418,375

250,923 204,802 1,092,811

1,824,573

1,548,536

552,597

419,930

Net current assets

1,271,976

1,128,606

Total assets less current liabilities

1,282,204

1,144,252

Creditors: amounts falling due after one year

329,543

163,859

Total net assets

952,661

980,393

The funds of the charity: Restricted income funds

7,546

39,055

Unrestricted income funds: Designated funds General funds

500,000 445,115

400,000 541,338

Total unrestricted funds

945,115

941,338

Total charity funds

952,661

980,393

Approved on33October October2017 2017and andsigned signedonon their behalf Approved by by the the trustees trustees on their behalf by by Karen Delin Chair of Trustees (Company no: 7487432) Karen Delin Chair of Trustees

Sarcoma UK Financial statements for the year ended 31 March 2017

Financial Statements

Statement Cash Flow Statement of cashof flows

Notes to the Financial Statements

For the year ended 31 March 2017

1. Accounting policies Note Cash flows from operating activities:

2017

Net cash provided by operating

323,807

323,528

Cash flows from investing activities Transferred (to) / from short term deposits Interest received

(3,114) 6,178

96,854 6,597

Purchase of fixed assets

(1,307)

(9,549)

Net cash provided by investing Change in cash and cash equivalents in the year Cash and cash equivalents at the beginning of the year Cash and cash equivalents at the end of the year

2016

1,757

93,902

325,564

417,430

1,092,811

675,381

1,418,375

1,092,811

a) Statutory information Sarcoma UK is a charitable company limited by guarantee and is incorporated in the United Kingdom. The registered office address (and principal place of business, if different from the registered office) is 49-51 East Road, London, N1 6AH b) Basis of preparation The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (September 2015) and the Companies Act 2006. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy or note. c) Public benefit entity The charitable company meets the definition of a public benefit entity under FRS 102. d) Going concern The trustees consider that there are no material uncertainties about the charitable company’s ability to continue as a going concern. The trustees do not consider that there are any sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next reporting period. e) Income Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the income have been met, it is probable that the income will be received and that the amount can be measured reliably. For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part,

Sarcoma UK Financial statements for the year ended 31 March 2017

is only considered probable when the amount can be measured reliably and the charity has been notified of the executor’s intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is a treated as a contingent asset and disclosed if material. Income received in advance of the provision of a specified service is deferred until the criteria for income recognition are met. f) Donations of gifts, services and facilities Donated professional services and donated facilities are recognised as income when the charity has control over the item or received the service, any conditions associated with the donation have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), volunteer time is not recognised so refer to the trustees’ annual report for more information about their contribution. On receipt, donated gifts, professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt. g) Interest receivable Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank. h) Fund accounting Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund. Unrestricted funds are donations and other incoming resources received or generated for the charitable purposes. Designated funds are unrestricted funds earmarked by the trustees for particular purposes. i) Expenditure and irrecoverable VAT Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be Sarcoma UK Financial statements for the year ended 31 March 2017

Financial Statements Notes to the financial statements For the year ended 31 March 2017

required and the amount of the obligation can be measured reliably. Expenditure is classified under the following activity headings:

• •

Costs of raising funds relate to the costs incurred by the charitable company in inducing third parties to make voluntary contributions to it, as well as the cost of any activities with a fundraising purpose

Expenditure on charitable activities includes the costs of raising sarcoma awareness, funding research and providing information and support, all undertaken to further the purposes of the charity and their associated support costs Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

j) Allocation of support costs Resources expended are allocated to the particular activity where the cost relates directly to that activity.

m) Debtors Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Support costs are those costs which do not in themselves constitute a charitable or fundraising activity, but are the central office functions necessary to support these activities. They include administration, finance, HR and office overhead costs. Governance costs are the costs associated with the governance arrangements of the charity. These costs are associated with constitutional and statutory requirements and include any costs associated with the strategic management of the charity’s activities. Support and governance costs are re-allocated to each of the activities on the following basis which is an estimate, based on staff time, of the amount attributable to each activity:

• • • •

Raising funds

27%

Research

19%

Information and support

29%

Awareness and education

25%

k) Operating leases Rentals payable under operating leases, where substantially all the risks and rewards of ownership remain with the lessor, are charged to the statement of financial activities on a straight line basis over the minimum lease term.

l) Tangible fixed assets Items of equipment are capitalised where the purchase price exceeds £250. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.

Sarcoma UK Financial statements for the year ended 31 March 2017

• •

Fixtures and fittings

5 years

Computer equipment

5 years

Notes to the financial statements

2. the Detailed comparatives For year ended 31 March 2017 for the statement of financial 2. Detailed comparatives for the statement of financial activities 2.

o) Creditors and provisions Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Donations and legacies

Unrestricted 1,086,920£

Restricted 105,981£

2016 Total £ 2016 Total 1,192,901£

Income from:activities Other trading Donations and legacies Investments

3,000 1,086,920 6,597

105,981-

3,000 1,192,901 6,597

Other income trading activities Total Investments

3,000 1,096,517 6,597

105,981-

3,000 1,202,498 6,597

Expenditure Total incomeon: Raising funds

1,096,517 220,511

105,981 6,637

1,202,498 227,148

Expenditure on: Charitable activities

738,026

129,400

867,426

Raising funds Total expenditure Charitable activities

220,511 958,537 738,026

6,637 136,037 129,400

227,148 1,094,574 867,426

Net income / (expenditure) and net Total expenditure movement in funds for the year

958,537 137,980

136,037 (30,056)

1,094,574 107,924

Net income / (expenditure) and net Reconciliation of funds: movement in fundsforward for the year Total funds brought

137,980 803,358

(30,056) 69,111

107,924 872,469

Reconciliation of funds: Total funds carried forward Total funds brought forward

941,338 803,358

39,055 69,111

980,393 872,469

Total funds carried forward

941,338

39,055

980,393

Detailed comparatives for the statement ofUnrestricted financial activities Restricted £ £ Income from:

n) Cash at bank and in hand Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of four months or less from the date of acquisition or opening of the deposit or similar account. 3.

Income from donations and legacies

3. Income from donations and legacies

1,101,363 Unrestricted 8,314£

251,129 Restricted £-

2017 Total £ 2017 1,352,492 Total 8,314£

1,101,363 2,030 8,314 1,111,707 2,030

251,129251,129 -

1,352,492 2,030 8,314 1,362,836 2,030

1,141,655 1,500 49,746 1,192,901 1,500

1,111,707

251,129

1,362,836

1,192,901

Income from donations and legacies Unrestricted £ Donations and gifts Legacies Donations and gifts Donated services Legacies

p) Pensions The charitable company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charitable company in an independently administered fund. The pension cost charge represents contributions payable under the scheme by the charitable company to the fund. The charitable company has no liability under the scheme other than for the payment of those contributions.

activities

Donated services

Restricted £

2016 Total £ 2016 1,141,655 Total 49,746£

Donated services include work by Touchline on the production of a Sarcoma UK report and hosting a supporter reception. Glyn Wilmshurst, CEO at Touchline, is a member of Sarcoma UK Board of Trustees. Donatedservices servicesinclude includework workbybyTouchline Touchline production a Sarcoma report Donated onon thethe production of aof Sarcoma UK UK report and and hosting a supporter reception. Glyn Wilmshurst, at Touchline, is a member of UK hosting a supporter reception. Glyn Wilmshurst, CEO at CEO Touchline, is a member of Sarcoma Board of Trustees. Sarcoma UK Board of Trustees.

Sarcoma UK Financial statements for the year ended 31 March 2017

Financial Statements Notes to the financial statements For the year ended 31 March 2017

1,094,574

For the year ended 31 March 2017 Grant making 5. Notes Grant 5. making to the financial statements 5.

Of the total expenditure £1,114,108 was unrestricted (2016: £958,537) and £282,638 was restricted (2016: £136,037).

248,373 178,652 440,401 227,148 Total expenditure 2016

For the year ended 31 March 2017 Grant making

2017 £

2016 £

2017 2016 Grants to institutions: £ £ Grant making University of Edinburgh 25,000 7,385 University of Aberdeen 118,872 Grants to institutions: University of Sheffield 38,319 2017 2016 University of Edinburgh 25,000 7,385 Aston University - £ 28,600 £ University of Aberdeen 118,872 University of Oxford (returned balance) (15,055) University 38,319 GrantsoftoSheffield institutions: Newcastle University 52,292 22,317 Aston University 28,600 University of Edinburgh 25,000 7,385 University College London 194,625 120,000 University of Oxford (returned balance) - - (15,055) University of Aberdeen 118,872 Institute of Cancer Research 144,865 Newcastle University 52,292 22,317 University of Sheffield 38,319 University of Manchester 25,000 University College London 194,625 - 120,000 Aston University 28,600 Royal Orthopaedic Hospital 24,800 Institute of Cancer Research 144,865 University of Oxford (returned balance) (15,055) Royal National Orthopaedic Hospital 25,000 University of Manchester 25,000 Newcastle University 52,292 22,317 Newcastle University (underspend) (301) Royal Orthopaedic Hospital 24,800 University College London 194,625 120,000 Aston University (underspend) (492) Royal National Orthopaedic Hospital 25,000 Institute of Cancer Research 144,865 Newcastle University (underspend) (301) University of Manchester 25,000 At the endOrthopaedic of the (underspend) year Hospital 490,789 Aston University (492) Royal 24,800 320,438 Royal National Orthopaedic Hospital 25,000 Newcastle University (underspend) (301) Atgrant the end year 490,789 320,438 details of the grant making activities disclosed 11-13 the report of the trustees. Full detailsFull of making activities are disclosedare on page xx ofon thepages report of theoftrustees. Aston University (underspend) (492)

633,695 278,258 Total expenditure 2017

174,534

310,259

1,396,746

5,388 Governance costs

7,710

8,214

7,162

(28,474)

(226,991) 42,954 Support costs

61,462

65,478

57,097

1,094,574 226,991 585,353 209,086

100,842

246,000

28,474

1,396,746

7,655 1,623 387 6,572 1,019 2,382 573 6,725 -

Sarcoma UK Financial statements for the year ended 31 March 2017

Legal & professional Insurance Bank charges Depreciation

9,002 -

10,021 2,382 573 6,725

8,100 3,807 62,996 7,819 90,305 12,313 50,950 1,674 6,818 95,839 14,091 1,057 580 1,082 PR & marketing Support services Awareness & education projects Information services Office costs Office communication costs Infrastructure development Membership subscriptions Trustees development, expenses & meeting costs

4,517 4,014 -

12,140 123,671 198 -

3,881

12,140 4,517 123,671 4,014 95,839 14,091 2,917 3,881

4,561 2,019 Fundraising appeals Donor relationship management

2,019

39,585 13,744 54,248 29,824 35,700 9,827 50,934 Fundraising fees Fundraising materials Events, participation & publicity costs

35,700 9,827 80,758

8,605 733 4,377 217 Travel, subsistence & conference fees

794

404

6,600

11,170 320,438 7,785 3,086 490,789 2,540 Other staff costs Research grants payable (note 5)

1,357 -

3,345 -

18,113 490,789

381,204 96,787 15,516 106,242 90,160 56,697

106,767 Staff costs (note 7)

£ £ £

Research

Cost of raising funds

Analysis of expenditure 4.4.Analysis of expenditure

472,169

£ £ £

Support costs

Charitable activities Information Awareness and and support education

Governance costs

2017 Total

2016 Total

Notes to the financial statements

Net income / (expenditure) for the year Full details of grant making of the report of320,438 the trustees. At the end ofactivities the yearare disclosed on page xx490,789

This is stated after charging / (crediting): Net income / (expenditure) for the year 6. Net expenditure for the year Full details of grant making activities are disclosed on page xx of the report of the trustees. 2017 2016 This is stated charging / (crediting): Thisafter is stated after charging / (crediting): £ £ 6. Net income / (expenditure) for the year 2017 2016 Depreciation 6,725 6,572 £ £ This is stated after charging / (crediting): Interest payable 6,178 6,597 Operating lease rentals: Depreciation 6,725 6,572 Property 66,690 45,093 2017 2016 Interest payable 6,178 6,597 Auditors’ remuneration (excluding VAT): £ £ Operating lease rentals: Audit 6,100 5,900 Property 66,690 45,093 Depreciation 6,725 6,572 Auditors’ remuneration (excluding VAT): Interest payable 6,178 6,597 Audit 6,100 5,900 Operating lease rentals: 7. Analysis of staff costs, trustee remuneration and expenses, and the cost of key Property 66,690 45,093 management personnel Auditors’ remuneration (excluding VAT): 7. Analysis of staff costs, trustee remuneration and expenses, 6,100 and the cost of key 5,900 Staff costs were asAudit follows: management personnel

2017 2016 costs were as follows: 7.Staff Analysis of staff costs, trustee remuneration expenses, and the cost of key 7. Analysis of staff costs, trustee and remuneration £ and expenses, £ management personnel of key management personnel 2017 2016 Salaries and wages 425,524 331,907 £ £ Staff Social costs aswere follows: security costsas follows: 42,458 33,355 Staffwere costs Employer’s contribution to defined contribution Salaries and wages 425,524 331,907 pension schemes 6,308 6,726 2017 2016 Social security costs 42,458 33,355 £ £ Employer’s contribution to defined contribution Accrued holiday pay (2,121) 9,216 pension schemes 6,308 6,726 Salaries and wages 425,524 331,907 472,169 381,204 Social security costs 42,458 33,355 Accrued holiday pay (2,121) 9,216 Employer’s contribution to defined contribution pension schemes 6,308 6,726 472,169 381,204 Accrued holiday pay (2,121) 9,216 472,169

and the cost

381,204

Sarcoma UK Financial statements for the year ended 31 March 2017

Financial Statements Notes to the financial statements

Notes to the financial statements

For the year ended 31 March 2017

Notes to the financial statements

Notes to the financial statements The following number of employees received employee benefits (excluding employer pension

The following number of employees received employee benefits (excluding employer pension costs national contributions) during the year between: For and the year ended 31and March 2017 insurance costs national insurance contributions) during the year between:

2017 2016 No. The following number of employees received employee benefitsNo. (excluding employer pension costs and national insurance contributions) during the year between: £60,000 - £69,999 1 1 2017 No.

2016 No.

The total employee benefits including pension and national insurance of the key insurance of the key - £69,999 1 contributions 1 and The total£60,000 employee benefitscontributions including pension national management personnel were £264,457 (2016: £222,742) incurred by 5 (2016:5) employees.

management personnel were £264,457 (2016: £222,742) incurred by 5 (2016:5) employees.

The charity trustees were not paid or received any other benefits from employment with the The charity trustees were not paid or received any other benefits from employment with the charity The in the year (2016: £nil). No charity trustee received paymentand fornational professional or other total employee including pension contributions key inbenefits the(2016: year (2016: No charity trustee receivedinsurance paymentofforthe professional or other services supplied charity to the charity £nil). £nil). management personnel were £264,457 (2016: £222,742) incurred by 5 (2016:5) employees.

services supplied to the charity (2016: £nil).

Trustees' represents or reimbursement travel and Theexpenses charity trustees werethe notpayment paid or received any other of benefits fromsubsistence employmentcosts with the Trustees’ expenses represent the payment or reimbursement of travel and subsistence costs totallingcharity £3,223 (2016: £5,721) incurred by 12 (2016: 12) members relating to ator in the year (2016: £nil). No charity trustee received payment forattendance professional other meetings of the trustees. The costs shown in note 4 for trustees’ development, expenses & totalling (2016: £5,721) services supplied to £3,223 the charity (2016: £nil). incurred by 12 (2016: 12) members relating to attendance at meeting costs also include costs relating to trustee meeting lunches, which are not direct trustee meetings of the trustees. The costs shown in note 4 for trustees’ development, expenses & expenses relatingexpenses to attendance at meetings of the trustees. Trustees' represents the payment or reimbursement of travel and subsistence costs

For the11. yearTangible ended 31 March fixed2017 assets 11. Tangible fixed assets

Notes to the financial statements For the year ended 31 March 2017 11. Tangible fixed assets valuation 11. TangibleCost fixedof assets At the start of the year Additions in the year Cost of valuation At the the end startofofthe theyear year At Additions in the year Cost of valuation Depreciation At ofthe theyear year At the the start end of Additions At the startinofthe theyear year Charge for the year Depreciation At the end of the year At the the end startofofthe theyear year At Charge for the year Depreciation Net book the At the start ofthe theatyear year endvalue of end of the year Charge for the year

meeting costs also include costs relating to trustee meeting lunches, which are not direct trustee

meeting costs also include costs relating to trustee meeting lunches, which are not direct trustee The average number of employees (head count based on trustees. number of staff employed) during the expenses relating to attendance at meetings of the year was as follows: 8.

8. Staff Staff numbers

numbers

2017 2016 The average of employees basedofon number of staff employed) during No. No. The average number of number employees (head count(head basedcount on number staff employed) during the the year was as follows: year was as follows: Raising funds 3 2 Research 2 1 Information and support 3 2017 2 2016 No. Awareness and education 2 2 No. SupportRaising funds 2 2 3 2 Governance 0 0 Research 2 1 Information and support Awareness and education Support Governance

Net book value at the At start Atthe the endof ofthe theyear year

totalling £3,223 (2016: £5,721) incurred by 12 (2016: 12) members relating to attendance at Staff numbers relating attendance meetings of the development, trustees. meetings ofexpenses the trustees. The to costs shown in at note 4 for trustees’ expenses &

Related party transactions

3 2 2 0

2 2 2 0

end of the year

12. 12. 12.

13.

Fixtures and fittings £ Fixtures and fittings 13,947£ Fixtures and fittings 13,947 13,947 £ -

Computer equipment £ Computer equipment 19,992£ 1,307 Computer equipment 19,992 21,299 £ 1,307

13,947 13,947 5,9992,859 13,947 5,999 8,858 2,859

19,992 21,299 1,307 12,294 3,866 21,299 12,294 16,160 3,866

33,939 35,246 1,307 18,293 6,725 35,246 18,293 25,018 6,725

5,089 5,999 8,858 2,859

5,139 12,294 16,160 3,866

10,228 18,293 25,018 6,725

5,089 7,948 8,858

5,139 7,698 16,160

10,228 15,646 25,018

9. Related party transactions There are no 9. related party transactions to disclose for 2017 (2016: none). Related party transactions There are no donations from related parties which are outside the normal course of business and There are no donations from related parties which are outside the normal course of business 10. Taxation no restricted donations from related parties.

and no restricted donations from related parties.

The charitable company is exempt from corporation tax asfor all2017 its income charitable and is There are no related party transactions to disclose (2016:isnone). applied for charitable purposes. Donated services include work by Touchline on the production of a Sarcoma UK report and 10. Taxation hosting a supporter reception. Glyn Wilmshurst at Touchline, is a member of Sarcoma UK

Board of Trustees.

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

10. Taxation

Total 33,939£ 1,307 Total 33,939 35,246 £ 1,307

At the start of the year 7,948 7,698 Net book value at thefor 5,089 5,139 of the above arecharitable used for charitable All of the All above assets areassets used purposes. purposes. end of the year Debtors At the start of the 7,948 7,698 All of the above assets areyear used for charitable purposes. 2017 Debtors 12. Debtors £ All of the above assets are used for charitable purposes. Other debtors 18,294 2017 102,149£ Debtors Prepayments Accrued income 77,839 Other debtors 18,294 2017 Prepayments 102,149 198,282 £ Accrued income 77,839 Other debtors 18,294 198,282 Prepayments 102,149 Accrued income 77,839 Creditors: amounts falling due within one year

16,498 2016 80,259£ 154,166 16,498 2016 80,259 250,923 £ 154,166 16,498 250,923 80,259 154,166

198,282 2017 £

250,923 2016 £

There are no donations from related parties which are outside the normal course of business and no restricted donations from related parties.

Total £

13. Creditors: amounts falling due within one year

Trade creditors 27,811 2017 13. Creditors: amounts falling due year Taxation andfalling social security 12,636 13. Creditors: amounts due within one yearwithin one £ Other creditors 300 Trade creditors 27,811 Accruals 18,653 2017 Taxation and social security 12,636 Grants payable 493,197 £ Other creditors 300 Trade creditors 27,811 Accruals 18,653 552,597 Taxation and social security 12,636 Grants payable 493,197 Other creditors 300 Accruals 18,653 552,597 Grants payable 493,197 552,597

15,646 10,228 15,646

2016 £

27,688 2016 11,947£ 300 27,688 93,812 2016 11,947 286,183 £ 300 27,688 93,812 419,930 11,947 286,183 300 93,812 419,930 286,183 419,930

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

Sarcoma UK Financial statements for the year ended 31 March 2017

Financial Statements Notes to the financial statements

Notes to the financial statements

For the year ended 31 March 2017

Notes to the financial statements

For the year endedfalling 31 March 14. Creditors: amounts due2017 after one due year after 14. Creditors: amounts falling

Notes to the financial statements 14. Creditors: amounts falling due after one year For the year ended 31 March 2017 Grants payable 14. Creditors: amounts falling due after one year Grants payable

one year

For the year ended 31 March 2017 year) 16a. Movements in funds 16a. Movements in funds(current (current year)

2017 £

2016 £

329,543

163,859 2017 2016 £ £ 329,543 163,859 329,543 163,859 2017 329,543 £

2016 163,859 £

15a. Analysis of net assets between funds (current year) Grants payable 329,543 General 15a.15a. Analysis netassets assets between funds (current year) unrestricted Designated Restricted 329,543 Analysis of of net between funds (current year) £ £ £

163,859 Total Funds 163,859 £

Tangible fixed assets

2,692General unrestricted Designated Net current assets of net assets 442,423 15a. Analysis between funds (current year) £ 829,543 £

7,536 10,228 Total Restricted Funds 10 £1,271,976 £

Long term liabilities Tangible fixed assets

- 7,536(329,543) 10,228 Total Restricted Funds 10 1,271,976 £ 952,661 £ 7,546 (329,543) 7,536 10,228

- 2,692 (329,543) General unrestricted Designated Net assets at 31 assets Net current 442,423 829,543 £ 500,000 £ March 2017 445,115 Long term liabilities (329,543) Tangible fixed assets 2,692 Net assets at 31 Net current 442,423 829,543 March 2017assets 445,115 500,000 15b. Analysis netliabilities assets between funds (prior year) Long of term (329,543)

10 7,546

1,271,976 952,661

(329,543)

Net assets at 31 General Total March 2017 445,115Designated 500,000 Restricted 7,546 Funds 952,661 unrestricted 15b. Analysis of net assets between funds (prior year) £ £ £ £ 2,802General 12,844 15,646 Total unrestricted Designated Restricted Funds 15b. Analysis net assets between funds (prior year) Net current assets of 538,536 26,211 15b. Analysis of net assets between funds (prior year)£ £ 563,859 £1,128,606 £

At 1 16a. Movements in funds (currentApril year) 2016 £ At 1 April Restricted funds: 2016 Sarcoma Trust 10 £ Infrastructure development 12,843 Restricted Research funds: 26,202 Sarcoma Trust 10Information and support Infrastructure development 12,843 Total restricted funds 39,055 Research 26,202 Information and support Unrestricted funds: Total restricted funds Research designated funds General funds Unrestricted funds: Total unrestricted funds Research designated funds General funds

- 2,802 (163,859) General unrestricted Designated Net assets at 31 assets Net current 538,536 563,859 £ 400,000 £ March 2016 541,338 Long term liabilities (163,859) Tangible fixed assets 2,802 Net assets at 31 Net current 538,536 563,859 March 2016assets 541,338 400,000 Long term liabilities Net assets at 31 March 2016

Sarcoma UK Financial statements for the year ended 31 March 2017

- 12,844(163,859) 15,646 Total Restricted Funds 26,211 1,128,606 £ 980,393 £ 39,055 (163,859) 12,844 15,646 26,211 39,055

1,128,606 980,393

(163,859)

541,338

400,000

39,055

980,393

Outgoing resources & losses £ Outgoing resources & losses £(5,307) (276,581) (750)(5,307) (282,638) (276,581)

251,129

750

(750)

At 31 March 2017 £ At 31 March 2017 10 £ 7,536 107,536 7,546-

314,208 (314,208)

7,546 500,000 445,115

Transfers £ Transfers £--

39,055 400,000 541,338

1,117,885

(282,638) (214,208) (899,900)

941,338 400,000 541,338

1,117,885 1,117,885

(1,114,108) (214,208) (899,900)

314,208(314,208)

945,115 500,000 445,115

Total funds Total unrestricted funds

980,393 941,338

1,369,014 1,117,885

(1,396,746) (1,114,108)

952,661 945,115

Total funds

980,393

1,369,014

(1,396,746)

952,661

Incoming resources & gains £ Incoming resources & gains £79,481 10,00016,50079,481 105,981 10,000 16,500

Outgoing resources & losses £ Outgoing resources & losses £(56,258) (53,279) (10,000)(56,258) (16,500) (53,279) (136,037) (10,000) (16,500)

Transfers £--

At 31 March 2016 £ At 31 March 2016 10 £ 12,843 26,202 1012,84326,202 39,055-

105,981

331,666 (331,666)

39,055 400,000 541,338

16b. Movements in funds (prior year) At 1 16b. Movements in funds (prior year) 16b. Movements in funds (prior year) April

Tangible fixed assets

Long term liabilities Tangible fixed assets

Incoming resources & gains £ Incoming resources & gains £250,379 750251,129 250,379

Restricted funds: Sarcoma Trust Infrastructure development Restricted Research funds: Sarcoma Trust Awareness and education Infrastructure development Information and support Research Total restricted funds Awareness and education Information and support Unrestricted funds: Total restricted funds Research designated funds General funds Unrestricted funds: Total unrestricted funds Research designated funds General funds

2015 At £ 1 April 2015 10 £ 69,101 1069,10169,111-

Transfers £

69,111 335,493 467,865

1,096,517

(136,037) (267,159) (691,378)

803,358 335,493 467,865

1,096,517 1,096,517

(958,537) (267,159) (691,378)

331,666(331,666)

941,338 400,000 541,338

Total funds Total unrestricted funds

872,469 803,358

1,202,498 1,096,517

(1,094,574) (958,537)

980,393 941,338

Total funds

872,469

1,202,498

(1,094,574)

980,393

Sarcoma UK Financial statements for the year ended 31 March 2017

Financial Statements Notes to the financial statements For the year ended 31 March 2017

Notes to the financial statements

Purposes of restricted funds: Sarcoma Trust These funds represent the amounts retained within the Sarcoma Trust after becoming a linked charity with Sarcoma UK. Infrastructure Development Expenditure against the fund relates to depreciation charges for the year, on assets purchased to develop the infrastructure of Sarcoma UK. Research These funds are to be used specifically towards research grants, as requested by the donor. Awareness and Education These funds are to be used specifically towards raising awareness and improving standards of treatment and care, as requested by the donor. Information and Support These funds are to be used specifically towards the provision of support and information for the sarcoma community, as requested by the donor.

Purposes of designated funds: Research These funds represent those designated by the trustees, towards research grants in 2017/18.

For year ended 31 March 2017 equivalents 18.theAnalysis ofof cash andand cash 18. Analysis cash cash equivalents At 1 April 18. Analysis of cash and cash equivalents 2016 At 1 April £ 2016 991,949

Cash at bank and in hand Notice deposits (less than three months) Cash at bank and in hand Net assets at the end of the Notice year deposits (less than three months)

100,862 £ 991,949 100,862 1,092,811

Net assets at the end of the 19. year Operating lease commitments1,092,811

Cash flows £ Cash 324,572 flows 992 £

Other £ changes -

At 31 March 2017 At 31 March £ 2017 1,316,521

£ -

101,854 £

Other changes

324,572

992 325,564

- -

325,564

1,316,521 101,854 1,418,375 1,418,375

The charity's total future minimum lease payments under non-cancellable operating leases is as follows forlease each of thecommitments following periods: 19.Operating Operating lease 19. commitments

The charity’s total future minimum payments non-cancellable operating Property Property Equipment Equipment The charity's total future minimum lease lease payments under under non-cancellable operating leases isleases as 2017 2016 2017 2016 is as follows each of the following follows for eachfor of the following periods: periods: £ £ £ £ Property Property Equipment Equipment Less than one year 16,985 16,049 473 411 2017 2016 2017 2016 £ £ £ £ 16,985 16,049 473 411 16,985

16,049

473

411

20. Legal status of the charity 16,985

16,049

473

411

Less than one year

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is limited to £1. 20. Legal status of the charity The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is limited to £1.

20. Legal status of the charity 17. Reconciliation of net income / (expenditure) to net cash flow from operating activities

Sarcoma UK Financial statements for the year ended 31 March 2017

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is limited to £1.

Sarcoma UK Financial statements for the year ended 31 March 2017

sarcoma.org.uk 020 7250 8271 info@sarcoma.org.uk @Sarcoma_UK uk.sarcoma 49-51 East Road, London N1 6AH

Sarcoma

Support Line

0808 801 0401

supportline@sarcoma.org.uk Registered as a charity in England and Wales (1139869) and in Scotland (SC044260) â&#x20AC;˘ A company limited by guarantee in England and Wales (7487432)